• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·POLYMED.NS
Share

Poly Medicure Limited Stocks

₹ 1444Last Updated 23.10.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₹ 1.70B

₹ 1444
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Poly Medicure Limited (PML) specializes in the production and distribution of a wide array of medical devices. Its extensive product portfolio encompasses a comprehensive range of infusion equipment, including IV cannulas, midline and arterial catheters, three-way stopcocks, various infusion sets (standard, safety winged, and measured volume), manifolds, extension lines, stylets/mandrins with luer locks, vial access spikes, central venous catheters, CVP manometers, needle-free connectors, pre-filled syringes, vascular access devices, and blood administration sets. The company also supplies diverse feeding solutions, such as nasogastric, infant, and gastro-duodenal feeding tubes, alongside umbilical catheters. Urology offerings include urine collection bags (with or without measured volume meters), Foley balloon catheters, irrigation sets, and general urine drainage catheters. For respiratory and anesthesia care, PML manufactures endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator and Bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. The company also provides oncology-specific products. Oxygen and respiratory therapy devices feature endobronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oropharyngeal airways, and various oxygen masks, including variable concentration, reservoir, fixed concentration, and aerosol therapy types. Its renal care segment comprises dialyzers, blood lines, complete dialysis systems, fistula needles, hemodialysis catheters, and peritoneal dialysis and transfusion sets. Surgical drainage products include closed wound suction units, underwater seal drainage systems, high-pressure vacuum bottles, Yankauer suction sets, and thoracic drainage catheters. For phlebotomy and blood diagnostics, PML supplies blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors. Blood bag systems are also available. Personal protective equipment (PPE) such as face shields and polymasks, along with viral transport medium kits, form part of its offering. Further miscellaneous medical disposables encompass insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. Established in 1995, the company is headquartered in New Delhi, India.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expensive' on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of POLYMED.NS is 1580 and suggests 9.4% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.10.2026 22:01

Solidigm Won't Go Public; New OpenAI Valuation: Key Points on the IPO by October 25

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds ramp up bets against euro to highest level since 2020

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026